Genentech Submits sBLA for Atezolizumab Plus Bevacizumab Combo to Treat Unresectable HCC
The company ’s application is based on results from the phase III IMbrave150 study of the regimen for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy. (Source: CancerNetwork)
Source: CancerNetwork - January 27, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news
Lower Hepatoma Risk With Earlier ALT Normalization During HBV Treatment Lower Hepatoma Risk With Earlier ALT Normalization During HBV Treatment
Earlier normalization of alanine aminotransferase (ALT) levels during treatment of chronic hepatitis B is independently associated with a reduced risk of hepatocellular carcinoma (HCC), researchers from South Korea report.Reuters Health Information (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - January 21, 2020 Category: Transplant Surgery Tags: Hematology-Oncology News Source Type: news
Imfinzi and tremelimumab granted Orphan Drug Designation in the US for liver cancer
AstraZeneca's Imfinzi (durvalumab) and tremelimumab, an anti-CTLA4 antibody and potential new medicine, have both been granted Orphan Drug Designation (ODD) in the US for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. (Source: World Pharma News)
Source: World Pharma News - January 20, 2020 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news
CARsgen Appoints Yong Fan as Senior Vice President of Global Regulatory Affairs
SHANGHAI, Jan 6, 2020 -- (Healthcare Sales & Marketing Network) -- CARsgen Therapeutics, a clinical-stage company committed to developing Chimeric Antigen Receptor T cell therapies for cancer, today announced appointment of Yong Fan, MD, as Senior Vice Pr... Biopharmaceuticals, Oncology, Personnel CARsgen Therapeutics, T cell, CAR-T, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 6, 2020 Category: Pharmaceuticals Source Type: news
Surgical Resection vs RFA for Very Early-stage HCC Surgical Resection vs RFA for Very Early-stage HCC
This analysis compared surgical resection to radiofrequency ablation as the first-line treatment for very early-stage hepatocellular carcinoma. Which option produced best recurrence-free survival?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 17, 2019 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
